Barthel H, Brendel M, Albert N, Boecker H, Bouter C, Brumberg J, Buchert R, la Fougère C, Gründer G, Hesse S, Kuwert T, Lange C, Langen KJ, Lohmann P, Meyer PT, Miederer I, Neumaier B, Rominger A, Schreckenberger M, Schulz JB, Yakushev I, Drzezga A. Updated Procedure Guideline of the German Society of Nuclear Medicine for Amyloid Brain PET Imaging 3.0. Nuklearmedizin. 2026 65(3):223-235.
Gründer G, Mertens L, Jungaberle A, Jungaberle H, Spangemacher M. Compassionate use of psilocybin for treatment-resistant depression in Germany. Lancet Psychiatry. 2026 13(2):91-93. Epub 2025 Sep 18.
Hart XM, Hirjak D, Eap CB, Eichentopf L, Fritze S, Lense XM, Scharf D, Schilling C, Schwind N, Post P, Wesner K, Gründer G. High Clozapine Serum Levels Do Not Improve Response: An Observational Study in Patients with Schizophrenia Treated with Clozapine in a Naturalistic Setting. Pharmacopsychiatry. 2026 May 20. [Epub ahead of print]
Mertens L, Koslowski M, Betzler F, Brand M, Evens R, Kärtner L, Jungaberle A, Jungaberle H, Majic T, Schmitz C, Ströhle A, Scharf D, Spangemacher M, Wolff M, Assadi Z, Bahri S, Becher L, Färber LV, Kirchen N, Kulakova E, Kunz L, Meijer A, Rohrmoser B, Wellek S, Berger M, Gründer G. Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial. JAMA Psychiatry. 2026 83(5):448-460. Epub 2026 Mar 18.
Mlynek E, Tan X, Lammertz SE, Schaffrath S, Gründer G, Schneider F, Frodl T, Mathiak K, Gaebler AJ. Disturbed Functional Connectivity Between Anterior Default Mode and Sensory Processing Regions Is Linked to Peripheral Inflammatory Markers and Psychopathology in Schizophrenia. Schizophr Bull. 2026 52(1):sbaf048. Epub 2025 Apr 23.